Fei Xu

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 395 citations

Medicine, Oncology, Pharmacology +11

Next-Generation Sequencing–Based Molecular Diagnosis of a Chinese Patient Cohort With Autosomal Recessive Retinitis Pigmentosa

Qing Fu, Feng Wang, Hui Wang et al. · Investigative Ophthalmology & Visual Science · 2013 · 100 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Molecular Mechanisms Leading to Null-Protein Product from Retinoschisin (RS1) Signal-Sequence Mutants in X-Linked Retinoschisis (XLRS) Disease

Camasamudram Vijayasarathy, Ruifang Sui, Yong Zeng et al. · Human Mutation · 2010 · 52 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +17

Novel RPE65 mutations associated with Leber congenital amaurosis in Chinese patients.

Fei Xu, Qiang Dong, Liang Liu et al. · PubMed · 2012 · 31 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Novel PRPF31 mutations associated with Chinese autosomal dominant retinitis pigmentosa patients.

Fei Xu, Ruifang Sui, Xiaofang Liang et al. · PubMed · 2012 · 26 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15